Dian Diagnostics Group (300244) Fair Value & Analysis
Healthcare · CN · Market cap 11.6B CNY
Analysis
Dian Diagnostics Group (300244) currently trades at ¥19.63, while our model-based Fair Value estimate is ¥14.51 — implying the stock looks roughly 26.1% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Dian Diagnostics Group Co.,Ltd. provides integrated medical diagnostics solutions with independent diagnostic services in China. The company offers laboratory supplies and kits; AI-assisted digital pathology diagnosis solutions, such as nucleic acid extraction and purification system, automatic liquid-based cytology slide preparation and staining system, digital pathology slide scanner, automated pathology slide staining system, genotyping DNA test kit, human papillomavirus nucleic acid detection kit, PCR system and detection system, and virus collection and preservation system; and multi-omics platform services. It also provides DP-TOF nucleic acid mass spectrometry solutions, including mass spectroscopy system, automatic sample processing system, respiratory pathogens multiple detection kit, and nucleic acid sample pretreatment reagent kit; and forensic drug testing products comprises diangio, hair drug trace tester and detector, and saliva and urine drug testing product series. I…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.